Immunotherapy combo shows promise in advanced lung cancer trial
NCT ID NCT03607539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the combination delayed cancer growth. Results showed that sintilimab improved progression-free survival, meaning the cancer took longer to worsen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab (an immunotherapy drug) combined with pemetrexed and platinum chemotherapy
What this could lead to
If successful, this combination could become a standard first-line treatment for advanced non-squamous lung cancer, helping patients live longer without their cancer growing.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients. Immunotherapy can cause immune-related side effects, and not everyone responds to the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, China